- Popping, Stephanie;
- Bade, Debora;
- Boucher, Charles;
- van der Valk, Mark;
- El-Sayed, Manal;
- Sigurour, Olafsson;
- Sypsa, Vana;
- Morgan, Timothy;
- Gamkrelidze, Amiran;
- Mukabatsinda, Constance;
- Deuffic-Burban, Sylvie;
- Ninburg, Michael;
- Feld, Jordan;
- Hellard, Margaret;
- Ward, John
Hepatitis B virus (HBV) and hepatitis C virus (HCV) affect more than 320 million people worldwide, which is more than HIV, tuberculosis (TB) and malaria combined. Elimination of HBV and HCV will, therefore, produce substantial public health and economic benefits and, most importantly, the prevention of 1.2 million deaths per year. In 2016, member states of the World Health Assembly unanimously adopted a resolution declaring that viral hepatitis should be eliminated by 2030. Currently, few countries have elimination programmes in place and even though the tools to achieve elimination are available, the right resources, commitments and allocations are lacking. During the fifth International Viral Hepatitis Elimination Meeting (IVHEM), 7-8 December 2018, Amsterdam, the Netherlands, an expert panel of clinicians, virologists and public health specialists discussed the current status of viral hepatitis elimination programmes across multiple countries, challenges in achieving elimination and the core indicators for monitoring progress, approaches that have failed and successful elimination plans.